A MULTI-CENTRE DOUBLE-BLIND RANDOMISED PLACEBO-CONTROLLED TRIAL OF ORAL ANTICOAGULATION IN SYSTEMIC SCLEROSIS-RELATED PULMONARY ARTERIAL HYPERTENSION

Grant number: 1062638 | Funding period: 2014 - 2019

Completed

Abstract

Scleroderma is an autoimmune disease that shortens life span by over 30 years. The main cause of death is pulmonary arterial hypertension (PAH), a condition of increased pressure in the lung vessels. Even in the era of 'advanced' PAH therapy, only 50% of patients are alive beyond 5 years. Formation of clots in the small blood vessels of the lung plays a major role in the development of PAH. In this clinical trial we aim to determine whether anticoagulation (treatment to prevent clotting) improves survival in scleroderma PAH.

University of Melbourne Researchers